GlassScriptPhysician profile
Maria Meris
NPI 1073628657
$1,512.29
in general payments reported to CMS, 2019-2025
11 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $348 · 2021: $241 · 2022: $78.24 · 2023: $151 · 2024: $318 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.33 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $438.33 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.32 | 2020-2025 | Tradjenta, Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $157.18 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $122.26 | 2019-2021 | |
| Lilly USA, LLC | $121.18 | 2019-2023 | Jardiance |
| Astellas Pharma US INC | $94.99 | 2024 | |
| Glaxosmithkline, LLC. | $67.16 | 2020-2025 | Arexvy, Shingrix |
| Amgen INC. | $35.06 | 2024 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $31.01 | 2021-2023 | Seglentis, Livalo |
| Sanofi Pasteur INC. | $23.57 | 2023 | |
| Novo Nordisk INC | $18.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Meris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.